Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 1/20 | 0.38 |
| ▸ | SMO | Q99835 | 12/20 | 0.36 |
| ▸ | LTA4H | P09960 | 2/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA7 | P43166 | 1/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.34 |
| ▸ | RORC | P51449 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
| ▸ | OGFRL1 | Q5TC84 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2015219 | 0.89 | CTSK (0.49) | CTSLCTSKSMOLTA4HOPRM1 | |
| SCHEMBL799013 | 0.77 | CA12 (0.39) | SMOLTA4HCA12CA7CA14 | |
| SCHEMBL13116899 | 0.75 | CA12 (0.37) | SMOLTA4HCA12CA7CA14 | |
| SCHEMBL18123295 | 0.75 | CA12 (0.37) | SMOLTA4HCA12CA7CA14 | |
| SCHEMBL14252363 | 0.75 | SMO (0.39) | SMOCA12CA7CA14 | |
| SCHEMBL48337 | 0.75 | — | — | |
| SCHEMBL15836240 | 0.75 | CA12 (0.58) | CA12CA7CA14 | |
| SCHEMBL2389051 | 0.74 | CTSL (0.33) | CTSLCTSK | |
| SCHEMBL5269734 | 0.72 | LTA4H (0.31) | LTA4H | |
| SCHEMBL14260165 | 0.72 | F10 (0.40) | SMOLTA4HCA12CA7CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008057420-A2 | EXTENDED TRITERPENE DERIVATIVES | PANACOS PHARMACEUTICALS, INC. (US) | 2008-05-15 | — | — | WO | disclosed |